英菲格拉替尼有耐药性吗,副作用大吗?

Infigratinib is a small molecule ATP-competitive tyrosine kinase inhibitor of FGFR that induces tumor cell death by reducing cancer cell proliferation. A phase II study found that patients with advanced cholangiocarcinoma who had failed previous chemotherapy and had FGFR2 fusion had significant effects and controllable safety after treatment with infigratinib. So, is there drug resistance and are there any serious side effects?

Is there resistance to infigratinib?

Infigratinib is also drug-resistant. Depending on each patient's physical condition, tolerance to the drug, and disease progression, the time it takes for patients with cholangiocarcinoma to develop resistance after treatment with Infigratinib, the specific resistance manifestations, and treatment methods will also be different. It is recommended that patients follow the doctor's instructions and do not change the dosage and usage at will to avoid adverse reactions that may affect the condition.

Does Infigratinib have any side effects?

Infigratinib has side effects. Common side effects include abdominal pain, dry mouth, nail toxicity, stomatitis, dry eye, fatigue, diarrhea, dry skin, hair loss, palmoplantar erythema syndrome, joint pain, eyelash changes, loss of appetite, blurred vision, vomiting, dysgeusia, constipation, etc.

Common laboratory abnormalities in clinical trials of infigratinib include increased creatinine, increased phosphate, increased calcium, decreased lymphocytes, decreased sodium, decreased phosphate, increased alkaline phosphatase, decreased hemoglobin, increased alanine aminotransferase, increased lipase, increased triglycerides, decreased platelets, increased aspartate aminotransferase, increased uric acid, decreased albumin, increased bilirubin, decreased leukocytes, decreased potassium, etc. Usually patients have different physiques and conditions, and the side effects are also different.

The recommended dose of infigratinib is 125 mg, taken orally once a day for 21 days, and then treatment is stopped for 7 days, with a cycle of 28 days. Patients need to take the drug on an empty stomach and at the same time every day. The above is the content of whether infigratinib is resistant and whether its side effects are serious.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: